Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 6;36(1):204–221. doi: 10.1523/JNEUROSCI.1751-15.2016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 the authors 0270-6474/16/360204-18$15.00/0

PMC Copyright notice

Figure 4. — Effect of the DOR antagonist naltrindole in rats with CFA-induced latent sensitization. A, PWTs of rats (n = 11) injected in the hindpaw with 50 μl of CFA subcutaneously. B, On day 30, these rats received 2.2 nmol naltrindole (a DOR antagonist) intrathecally. C, On day 48, some of the rats (n = 8) received 1 mg/kg naltrindole subcutaneously. Holm-Sidak's post hoc tests of two-way ANOVA: *p < 0.05, ***p < 0.001 compared with baseline (0 d or 0 min). D, PWTs of rats (n = 8) without intrathecal catheters that were injected in the hindpaw with 50 μl of saline subcutaneously. E, On day 30, the saline-injected rats (n = 8) received naltrindole subcutaneously (1 mg/kg).